Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI-608 plus FOLFIRI vs FOLFIRI in metastatic colorectal cancer (second-line)
CTR20170486Phase 3Active
- Sponsor
- Boston Molecules
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of napabucasin in metastatic colon cancer (mCRC), sponsored by Boston Molecules. Started May 2017; status: active.
02
Drugs
napabucasin
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20170486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170486.